ArticleNPJ precision oncology2022

PALB2 or BARD1 loss confers homologous recombination deficiency and PARP inhibitor sensitivity in prostate cancer.

Kasia M Dillon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.